Drug intelligence / Profile preview

gefitinib + sirolimus

Development stage: Unknown
Lead developer: UCLA Jonsson Comprehensive Cancer Center
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of gefitinib, an EGFR tyrosine kinase inhibitor, and sirolimus, an mTOR inhibitor. This combination targets two interconnected signaling pathways involved in cancer cell growth and proliferation. The dual inhibition approach aims to overcome resistance mechanisms that can develop with single-agent therapy.

Targets

EGFR (Epidermal growth factor receptor)Mechanistic target of rapamycin complex 1

Beyond the preview

Go deeper on gefitinib + sirolimus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gefitinib + sirolimus.

Explore the full profile